Abstract
Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.
Keywords: Cardiovascular disease, immune system, Toll-like receptors, signaling pathway, atherogenesis, stroke.
Current Pharmaceutical Design
Title:Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease
Volume: 24 Issue: 17
Author(s): Seyed Mostafa Parizadeh, Maryam Ghandehari, Motahareh Heydari-majd, Sima Seifi, Ramin Mardani, Seyed Mohamadreza Parizadeh, Majid Ghayour-Mobarhan, Gordon A. Ferns, Seyed Mahdi Hassanian*Amir Avan*
Affiliation:
- Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran
- Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Cardiovascular disease, immune system, Toll-like receptors, signaling pathway, atherogenesis, stroke.
Abstract: Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.
Export Options
About this article
Cite this article as:
Parizadeh Mostafa Seyed , Ghandehari Maryam , Heydari-majd Motahareh , Seifi Sima , Mardani Ramin , Parizadeh Mohamadreza Seyed , Ghayour-Mobarhan Majid , Ferns A. Gordon , Hassanian Mahdi Seyed *, Avan Amir *, Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease, Current Pharmaceutical Design 2018; 24 (17) . https://dx.doi.org/10.2174/1381612824666180614090224
DOI https://dx.doi.org/10.2174/1381612824666180614090224 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced Echocardiographic Imaging of the Congenitally Malformed Heart
Current Cardiology Reviews The Role of Sympathetic Nervous System in the Progression of Chronic Kidney Disease in the Era of Catheter Based Sympathetic Renal Denervation
Current Clinical Pharmacology PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Traditional Chinese Medicine Network Pharmacology in Cardiovascular Precision Medicine
Current Pharmaceutical Design Mechanisms of Beta-Blockers Action in Patients with Heart Failure
Reviews on Recent Clinical Trials Re-Discovering PDE3 Inhibitors - New Opportunities for a Long Neglected Target
Current Topics in Medicinal Chemistry Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Retinal Vascular Features for Cardio Vascular Disease Prediction: A Review
Recent Patents on Computer Science Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis
Reviews on Recent Clinical Trials Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Role of Wnt Signaling in Tissue Fibrosis, Lessons from Skeletal Muscle and Kidney
Current Molecular Medicine The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Cardiac Autonomic Nervous System in Heart Failure: Imaging Technique and Clinical Implications
Current Cardiology Reviews Impact of the Fontan Operation on Organ Systems
Cardiovascular & Hematological Disorders-Drug Targets Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Current Enzyme Inhibition